To assess multimorbidity burden and its association with clinical outcomes in adults with heart failure (HF) according to sex, age, and HF type. DESIGN: Retrospective cohort study. SETTING: Five healthcare delivery systems across the United States. PARTICIPANTS: Adults with HF (N=114,553). MEASUREMENTS: We characterized participants with respect to the presence of 26 chronic conditions categorized into quartiles based on overall burden of comorbidity (<5, 5-6, 7-8, ≥9). Outcomes included all-cause death and hospitalization for HF or any cause. Multivariable Cox regression was used to evaluate the adjusted association between categorized burden of multimorbidity burden and outcomes. RESULTS: Individuals with more morbidities were more likely to die than those with fewer then 5 morbidities (5-6 morbidities: adjusted hazard ratio (aHR)=1.27 (95% confidence interval (CI)=1.24-1.31; 7-8 morbidities: aHR=1.52, 95% CI=1.48-1.57; ≥9 morbidities: aHR=1.92, 95% CI=1.86-1.99). There was a graded, higher adjusted rate of any-cause hospitalization associated with 5 or 6 (aHR=1.28, 95% CI=1.25-1.30), 7 or 8 (aHR=1.47, 95% CI=1.44-1.50), or 9 or more (aHR=1.77, 95%
which may complicate clinical management and treatment decision-making. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] Previous studies have shown that most adults with HF have 5 or more chronic medical conditions. [1] [2] [3] As a consequence, healthcare providers face the prospect of simultaneously managing HF and multiple chronic conditions, [4] [5] [6] [7] 11, 12 and it can be challenging to apply clinical practice guidelines that do not consider how multimorbidity contributes to undesirable outcomes such as adverse interactions among drugs and diseases. 4 Furthermore, in selected studies, multimorbidity has been found to be associated with higher risks of hospitalization and death in individuals with HF. [3] [4] [5] [6] As a previous study found, "most randomized clinical trials have either explicitly excluded older adults or have enrolled only relatively healthy older patients. As a result, the generalizability of the results of most major clinical trials to older patients, especially those >75 years of age with multimorbidity, is uncertain." 13 Our rationale in pursuing the current investigation was to fill gaps in knowledge that the previous study highlighted by better characterizing the association between multimorbidity and adverse outcomes in individuals with HF cared for in real-world clinical settings. Gaining additional insight into these relationships is crucial to advancing the care of the growing population of individuals with HF.
In addition, over recent years, HF epidemiology has changed, with a greater increase in the prevalence of HF with preserved ejection fraction (HFpEF), especially in older adults, than of that with reduced ejection fraction (HFrEF) or borderline ejection fraction (HFbEF). 10, 14 Through the Cardiovascular Research Network (CVRN), 15 we sought to better define the association between burden of multimorbidity and clinical outcomes in adults with HF according to sex, age, and HF type.
METHODS

Source Population
The source population included members of 5 participating healthcare delivery systems within the CVRN. Sites included Kaiser Permanente Northern California, Kaiser Permanente Colorado, Kaiser Permanente Northwest, Kaiser Permanente Southern California, and Fallon Health in Massachusetts. These healthcare systems provide care to an ethnically and socioeconomically diverse population across varying practice settings and geographically diverse areas. Each site also developed and maintained a virtual data warehouse (VDW) that served as the primary data source for subject identification and characterization. 15, 16 A VDW is a distributed standardized data resource comprising electronic datasets at each CVRN site, populated with linked demographic, administrative, ambulatory pharmacy, outpatient laboratory test results, and healthcare use (ambulatory visits and network and nonnetwork hospitalizations with diagnoses and procedures) data for members receiving care at participating sites. 15, 16 Institutional review boards at the participating sites approved the study, and a waiver of consent was obtained because of the observational nature of this study.
Study SAMPLE
We first identified all persons aged 21 and older with diagnosed HF based on them having been hospitalized with a primary discharge diagnosis of HF or having 3 9 . Previous studies have found a positive predictive value of greater than 95% for admissions with a primary discharge diagnosis of HF based on these codes when compared with chart review using Framingham clinical criteria. 15, 16 For the outpatient HF definition, we required 3 or more ambulatory visits with associated HF diagnoses, with 1 or more of the visits being to a cardiologist to enhance specificity for having HF.
We ascertained information on quantitative and qualitative assessments of left ventricular systolic function from the results of echocardiograms, radionuclide scintigraphy, other nuclear imaging modalities, and left ventriculography test results available from site-specific databases complemented by manual chart review. We classified participants into categories of HFpEF, HFrEF, and HFbEF. We defined HFpEF as reported left ventricular ejection fraction of 50% or greater or based on a physician's qualitative assessment of preserved or normal systolic function. 17 HFrEF was defined as a reported left ventricular ejection fraction of 40% or less or based on a physician's qualitative assessment of moderate, moderate to severe, or severe systolic dysfunction. 17 HFbEF was defined as a reported left ventricular ejection fraction between 41% and 49% or based on a physician's qualitative assessment of mildly reduced systolic function. 17 
Assessment of Multimorbidity Burden
We selected 26 conditions for analysis based on their high prevalence or previously reported association with poor outcomes in individuals with HF. We included 14 of the 19 comorbidities that the U.S. Department of Health and Human Services Strategic Framework on Multiple Chronic Conditions recommends. 18 The conditions included in this investigation also incorporated the 10 conditions recently specified under a task order from the Centers for Medicare and Medicaid Services (CMS) to systematically narrow the list of chronic conditions identified in the CMS Chronic Condition Data Warehouse to those most relevant to risk of hospitalization. 19 The 26 chronic conditions included in our analysis were acute myocardial infarction, unstable angina pectoris, coronary heart disease, ventricular tachycardia or fibrillation, mitral or aortic valve disease, atrial fibrillation, ischemic stroke or transient ischemic attack, peripheral arterial disease, diabetes mellitus, dyslipidemia, hypertension, chronic kidney disease, replaced by major bleeding, anemia, arthritis, chronic obstructive pulmonary disease, asthma, cancer, chronic liver disease, osteoporosis, thyroid disease, dementia, depression, hearing impairment, mobility impairment, and visual impairment. We did not have systematically available information on mental disorders such as autism and schizophrenia or for human immunodeficiency virus infection status. All conditions were identified using previously described methods [20] [21] [22] [23] using data from inpatient medical records, emergency and ambulatory diagnoses and procedures, dispensed prescription medications, and laboratory test results found in the VDW (definitions and specific codes included in Supplementary Appendix S2).
Outcomes
Follow-up occurred from the index date of meeting eligibility criteria through December 31, 2013. Participants were censored if they disenrolled from the health plan or at the end of study follow-up. Hospitalizations were identified from each site's VDW, and admissions for HF were based on a primary discharge diagnosis for HF using the same ICD-9 inclusion codes. Deaths were identified from hospital and billing claims databases, administrative health plan databases, state death certificate registries, and Social Security Administration files as available at each site. These approaches have yielded greater than 97% vital status information in prior studies.
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Data Analysis
All analyses were performed using SAS version 9.3 (SAS Institute, Inc., Cary, NC). The 26 chronic conditions included in this study were summed for each study subject to create a multimorbidity count, and we categorized the study population into 4 multimorbidity burden groups based on the sample distribution (<5, 5-6, 7-8, ≥ 9 chronic conditions). We compared differences in baseline participant characteristics and medication use patterns across the comparison multimorbidity burden groups using chi-square tests for categorical variables and t-tests for continuous variables. Cox proportional hazards regression models were used to examine associations between burden of multimorbidity and each outcome of interest after adjustment for potential confounding variables. Covariates included study site; demographic characteristics (age, sex, race, ethnicity), selected laboratory and physiological variables (systolic blood pressure, body mass index, estimated glomerular filtration rate, hemoglobin, serum potassium), and receipt of relevant cardiac medications within 120 days before the index date based on dispensed outpatient prescriptions (angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, calcium channel blockers, beta-blockers, warfarin, digoxin, statins, antiplatelet agents). Consistent with the objectives of our study, we also performed separate analyses stratified according to sex, age (<55, 55-64, 65-74, 75-84, 85-94, ≥ 95), and HF type (HFpEF, HFrEF, HFbEF).
RESULTS
Study Population
We identified 114,553 eligible adults with HF for whom left ventricular systolic function data were available. Mean age was 75.0AE12.8, 45.9% were female, and 73.5% were white (Table 1) . Subjects had a mean of 6.0 chronic conditions, with 26.4% having 0 to 4, 29.3% having 5 or 6, 26.9% having 7 or 8, and 17.4% having 9 or more of the 26 chronic conditions examined at the time of study entry. With regard to type of HF, 51.3% had HFpEF, 34.3% had HFrEF, and 14.4% had HFbEF. Frequency distribution of chronic conditions overall and stratified according to multimorbidity burden are summarized in Table 2 . Use of all classes of cardiovascular medications was higher with greater burden of multimorbidity at entry (Supplementary Appendix S1).
Association Between Burden of Multimorbidity and Principal Study Outcomes
Higher comorbidity burden was associated with higher allcause mortality than lower comorbidity burden (<5 comorbidities) in crude analyses (5-6 comorbidities: hazard ratio Figure 1B) .
A similar pattern between multimorbidity burden and hospitalizations from any cause was observed (5-6 comorbidities: HR=1.12, 95% CI=1.10-1.14; 7-8 comorbidities: HR=1.31, 95% CI=1.29-1.33; ≥9 comorbidities: HR=1.65. 95% CI=1.62-1.69) (vs <5 comorbidities). After adjustment for potential confounders, greater multimorbidity remained associated with a graded higher risk of hospitalization (5-6 comorbidities: aHR=1.28, 95% CI=1.25-1.30; 7-8 comorbidities: HR=1.47, 95% CI=1.44-1.50; ≥9 comorbidities (HR=1.77, 95% CI=1.73-1.82) ( Figure 1C ).
Association Between Burden of Multimorbidity and Outcomes According to Sex
Higher comorbidity burden was associated with higher allcause mortality in men and women when stratified according to sex (men: 5-6 comorbidities: aHR=1.28, 95% CI=1.23-1.33; 7-8 comorbidities: aHR=1.59, 95% CI=1.53-1.66; ≥9 comorbidities: aHR=2.01, 95% CI=1.92-2.10) (women: 5-6 comorbidities: aHR=1.25, 95% CI=1.19-1.30; 7-8 comorbidities: aHR=1.43, 95% CI=1.37-1.50; ≥9 comorbidities: aHR=1.82, 95% CI=1.73-1.91) ( Figure 1A) . Similar trends were found in the multivariable adjusted associations between greater multimorbidity and HF-specific and any-cause hospitalization in men and women ( Figure 1B, C) .
Association Between Burden of Multimorbidity and Outcomes According to Age
Across a wide age range, there was a consistent association between higher burden of multimorbidity and worse clinical outcomes, although the effect of multimorbidity burden on outcomes was greater in younger than older adults (Figures 2A-C) . (Figure 2A ). Similar trends were found in the multivariable associations between greater morbidity burden and HFspecific and any-cause hospitalizations, in which the strength of association was less prominent with older age (Figure 2B, C) .
Association Between Burden of Multimorbidity and Outcomes According to Type of HF
For the outcome of all-cause death, in subjects with confirmed HFpEF, greater morbidity was associated with greater risk of dying from any cause (5-6 comorbidities: aHR=1. 25 Figure 1 . Multivariable association between burden of multimorbidity and risk of (A) death from any cause, (B) heart failurerelated hospitalization, or (C) hospitalization for any cause in adults with heart failure, overall and stratified according to sex.
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DISCUSSION
In this large, population-based study of adults with HF, after adjustment, we found a graded, increasing risk of adverse clinical outcomes with greater multimorbidity burden. Similar trends were found in men and women, across a broad age spectrum, and in those with preserved, Figure 2 . Multivariable association between burden of multimorbidity and risk of (A) death from any cause, (B) heart failurerelated hospitalization, or (C) hospitalization for any cause in adults with heart failure stratified according to age. reduced, and borderline ejection fraction findings. Worse prognoses associated with greater multimorbidity burden were especially prominent in persons younger than 65, an important finding that highlights that the clinical implications of multimorbidity for the health of populations and individuals are not limited to older adults with HF. 24 Several previous studies have examined the association between multimorbidity burden and clinical outcomes in individuals with HF. 5, 25, 26 The HF Pilot Survey of the EURObservational Research Program of the European Society of Cardiology examined the association between multimorbidity burden and adverse outcomes in 3,226 individuals with HF. 25 Individuals with 3 or more Figure 3 . Multivariable association between burden of multimorbidity and risk of (A) death from any cause, (B) heart failurerelated hospitalization, or (C) hospitalization for any cause in adults with heart failure stratified according to type of heart failure.
comorbidities were approximately 9 times as likely as those with none of the 10 comorbidities examined to die during 1 year of follow-up and 5 times as likely to be hospitalized for HF. 25 Similarly, in a study of 18,300 fee-for-service Medicare beneficiaries with HF, those with 5 or more chronic conditions had twice the 1-year risk of dying as those with fewer than 3 conditions. 5 Finally, findings from an outpatient cohort of veterans with HF (n=2,843 HFpEF, n=6,599 HFrEF) also revealed that individuals with HF with 8 or more non-cardiac-related comorbidities had a 60% higher relative risk of being hospitalized for any cause than those with no comorbidities. 26 Our work builds on these prior studies within the context of a larger, more demographically diverse population of adults with confirmed HFpEF, HFrEF, and HFbEF and examines an expanded set of comorbidities and outcomes. Although we found that the associations between greater multimorbidity and death and hospitalization were strongest in individuals younger than 65, the effect on a population-level is largest in older adults with HF because the morbidity burden is highest in the oldest adults.
Our study had several strengths and limitations that should be considered in interpreting the study findings. Although we did not individually adjudicate each subject's records to confirm clinical HF, prior studies in our population have shown high positive predictive value of our algorithms to identify individuals with HF. 27, 28 Our study included a large sample of individuals with confirmed HFbEF. Few studies have included this interesting group of individuals with HF, who some have asserted have clinical characteristics and outcomes different from the characteristics and outcomes of those with HFpEF and HFrEF. 29 Across the range of left ventricular systolic function, we observed similar findings in relation to multimorbidity burden. We also relied on automated clinical databases for ascertainment of presence of comorbidities and use of medications, which may have led to some misclassification. Our study was conducted in an insured population living in 5 geographic areas of the United States, but we believe that our findings are generalizable to other healthcare settings and uninsured persons in the United States in real-world practice settings, given the diverse nature and large size of the studied population. Another study limitation was that detailed information about the duration, severity, and extent of the chronic conditions studied was unavailable, although our approach to characterizing multimorbiditysumming the number of chronic conditions-addressed the limitation of considerable heterogeneity and complexity of existing approaches to examining burden of multimorbidity. Some examples of the most commonly used approaches include the Charlson and Elixhauser indices, which although often used in observational research studies of prognosis, may be less practical and applicable for use by healthcare providers delivering face-to-face care in real time to people in real-world clinical settings. 30 Our straightforward approach to characterizing burden of multimorbidity in individuals with HF may be readily applied as healthcare systems continue to implement novel informatics approaches to assist in clinical decision-making at the point of care. 31 Our findings underscore the importance of the association between multimorbidity burden and adverse outcomes in individuals with various types of HF, middle-aged and older persons, and men and women. Multimorbidity in individuals with HF substantially increases the complexity of their care, as practitioners face the challenge of managing multiple conditions simultaneously that may increase therapy-associated side effects. 4, 28, [32] [33] [34] [35] With the aging of the U.S. population, the numbers of individuals with HF will increase dramatically over the coming decades, 1,2 especially those with a high burden of multimorbidity, which will place greater demands on healthcare providers and the systems in which they work. A clearer understanding of the effect of multimorbidity burden on important outcomes in individuals with HF will help healthcare providers and their patients and their caregivers in discussions about their prognosis. Clinical trials of treatments for HF have usually excluded older adults with a high burden of comorbidity, which has led to evidence gaps in how to treat this medically complex, vulnerable population optimally. [32] [33] [34] In conclusion, our study highlights the uniformly negative prognosis of greater morbidity burden for multiple clinical outcomes. Our findings also suggest that large observational studies can help identify important high-risk subgroups of individuals with HF and inform the design of future randomized trials focused on individuals at highest risk of adverse outcomes.
